醛固酮合成酶抑制剂治疗原发性醛固酮增多症的可行性探讨  

Feasibility of Aldosterone Synthase Inhibitor for the Treatment of Primary Aldosteronism:Viewpoint

作　　者：董徽[1] 左毓杰 蒋雄京[1] DONG Hui;ZUO Yujie;JIANG Xiongjing(Department of Cardiology,National Center for Cardiovascular Diseases and Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院北京协和医学院国家心血管病中心阜外医院心内科,北京100037

出　　处：《中国循环杂志》2024年第9期920-923,共4页Chinese Circulation Journal

基　　金：国家自然科学基金(81700440);中国医学科学院医学与健康科技创新工程(2021-I2M-C&T-B-026,2021-I2M-C&T-B-027);中央高水平医院临床科研业务费(2023-GSP-QN-10)。

摘　　要：近年来,醛固酮合成酶抑制剂(aldosterone synthase inhibitor,ASI)治疗高血压受到广泛关注,osilodrostat、baxdrostat、lorundrostat和dexfadrostat等药物相继被研发并开展了一系列临床研究。本文拟对当前ASI治疗高血压的临床研究结果及存在的问题和争议进行阐述,并探讨ASI治疗原发性醛固酮增多症的可行性。In recent years,aldosterone synthase inhibitor(ASI)has attracted widespread attention as a treatment option for hypertension.Drugs such as osilodrostat,baxdrostat,lorundrostat,and dexfadrostat have been developed and the therapeutic effects have been evaluated in a series of clinical studies.This article intends to elaborate current clinical research results,problems,and controversies of ASI for the treatment of hypertension,and explore the feasibility of using ASI for the treatment of primary aldosteronism.

关 键 词：原发性醛固酮增多症 醛固酮合成酶抑制剂 醛固酮 

分 类 号：R54[医药卫生—心血管疾病]